Current Imaging Evaluation of Tumor Response to Advanced Medical Treatment in Metastatic Renal-Cell Carcinoma: Clinical Implications

Caruso, Martina; Romeo, Valeria; Stanzione, Arnaldo; Buonerba, Carlo; Lorenzo, Giuseppe Di; Maurea, Simone

doi:10.3390/app11156930

Cited by 5 publications

(1 citation statement)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consequently, the 5-year survival rate for advanced RCC has increased to nearly 20%[ 2 ]. Recent studies have shown that immunotherapy and target therapy combined with immunotherapy have led to positive results in the PFS of advanced RCC patients[ 14 , 15 ].…”

Section: Discussionmentioning

confidence: 99%

Successful apatinib treatment for advanced clear cell renal carcinoma as a first-line palliative treatment: A case report

Wei¹,

Mei²,

Hu³

2022

WJCC

View full text Add to dashboard Cite

BACKGROUND Apatinib is an orally bioavailable small-molecule receptor tyrosine kinase inhibitor. In December 2014, the China Food and Drug Administration made it the first anti-angiogenic therapy to be approved for treating metastatic gastric cancer. It was specifically designated as a third-line or later treatment for metastatic gastric cancer. CASE SUMMARY Here, we present a case of advanced renal cell carcinoma (RCC) with multiple metastases (Stage IV) in a 48-year-old male with an extremely poor general status (Karnofsky 30%). He was initially given pazopanib as a targeted therapeutic. However, he experienced severe adverse reactions within two weeks, including grade IV oral mucositis. We, thus, tried switching his targeted treatment to an apatinib dose of 250 mg once daily since April 2018. The patient demonstrated striking benefits from this switch to the apatinib palliative treatment. Nearly one month later, his pain and other associated symptoms were alleviated. The patient was able to move freely and had an excellent general status (Karnofsky 90%). His progress has been followed up with regularly, allowing for a documented progression-free survival interval of approximately 32 mo. CONCLUSION This case suggests that, like other multi-target drugs, apatinib may be a useful first-line therapeutic drug for advanced RCC. It may be a particularly helpful curative option when patients are found to be intolerant of other targeted drugs.

show abstract

Section: Discussionmentioning

confidence: 99%